Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $140 from $137 and keeps a Buy rating on the shares. The firm met with management and updated its model to reflect the company’s distribution fix and its oncology commercial infrastructure that they are building out to include the EU as well.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics’ New Drug Application Accepted by FDA
- Corcept Therapeutics announces FDA acceptance of relacorilant NDA
- Corcept Therapeutics’ Miricorilant Study: A Potential Game-Changer for Liver Disease Treatment
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
- Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant